The conference aimed at providing pediatric dermatology clinicians with the latest in the specialty begins tomorrow in Toronto, Ontario.

Ahead of the SPD's Annual Meeting in Toronto, share with us: What do you hope to learn?

Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024.

In today’s podcast, Silverberg discusses topical therapeutics for vitiligo and clinical excellence.

Renata Block, MMS, PA-C, and Amber Blair, MMS, PA-C, discuss the gratification of helping patients and the excitement of being on the cutting edge of research.

The post-hoc analysis evaluated the relationship between lebrikizumab serum concentration levels and sustained clinical response after lebrikizumab discontinuation.

Stephen Tyring, MD, PhD, MBA, covers the burden of antimicrobial resistance and the need for alternative treatments.

Martin Zaiac, MD, gave insight on potential risks associated with manipulation of nails, hygiene, and when it is necessary to see a specialist.

Laura Bush reflects on her term as SDPA president, discussing achievements, challenges, and the future of dermatology PAs in health care.

Rob Casquejo, PA-C, spoke with Dermatology Times on new and upcoming medications, addressing unmet needs, and social media misinformation.

Ethan Sims, MD, spoke with Dermatology Times on having positive conversations, cutting down on waste, and how to get involved in change.

Gottlieb reviews her lecture from the Society for Investigative Dermatology Annual Meeting.

Ahead of the next 3 months of the year, Dermatology Times wants to know what conferences and meetings you plan to attend between July and September. Share your thoughts with us by June 26.

Catch up on all clinical pearls from the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

Jonathan Silverberg, MD, PhD, MPH, and Melinda Gooderham, MSc, MD, FRCPC, debated which patients are a contender for systemic therapy.

The data, presented at RAVE 2024, continued a positive trend, building upon strong phase 1 results of rademikibart for patients with AD.

Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.

Catch up on coverage from the last day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

The phase 3b/4 LEVEL-UP study assessed adolescents and adults with moderate to severe atopic dermatitis.

Roflumilast cream 0.15% is being evaluated for patients with mild to moderate atopic dermatitis down to 6 years.